摘要
目的 探讨老年非小细胞肺癌患者参芪扶正注射液与化疗治疗临床疗效,并观察其对患者免疫功能及血清肿瘤标志物癌胚抗原（carcino embryonie antigen,CEA）,糖类抗原19-9（carbohydrate antigen 19-9,CA19-9）,细胞角蛋白19片段（cytokeratin 19fragment,CYFRA21-1）,神经元特异性烯醇化酶（neuronspecific enolase,NSE）指标的影响。方法 选取非小细胞肺癌80例患者,其中采用紫杉醇＋卡铂化疗者为对照组,40例;于对照组治疗基础上采用参芪扶正注射液治疗者为治疗组,40例。分别于治疗4周期后评价临床疗效,并记录治疗期间不良反应情况;评价2组患者治疗前、治疗4周期后中医证候积分,采用卡氏评分（Karnofsky performance score,KPS）评价2组患者治疗前、后生存质量情况;检测2组治疗前、后免疫功能及肿瘤标志物指标。结果 治疗组治疗临床总有效率65.0%,明显高于对照组42.5%（χ2=4.07,P=0.04）;治疗组治疗期间不良反应37.5%,明显低于对照组62.5%（χ2=5.00,P=0.02）。2组患者治疗后中医证候积分明显低于治疗前,卡氏评分明显高于治疗前,且治疗组治疗后中医证候积分明显低于对照组,卡氏评分明显高于对照组（P〈0.05）。治疗后,治疗组患者各项免疫功能指标与治疗前比较差异无统计学意义,而对照组治疗后各项免疫功能指标明显低于治疗前,且与治疗组比较差异有统计学意义（P〈0.05）。2组患者治疗后各项肿瘤标志物指标明显下降,且治疗组各项指标下降程度较对照组显著（P〈0.05）。结论 辅以参芪扶正注射液治疗老年非小细胞肺癌对其免疫功能影响较小,有助于促进患者血清肿瘤标志物水平下降及临床症状的改善,降低不良反应,提高临床疗效,有助于改善其生活质量。
Objective To investigate the clinical efficacy of Shenqi Fuzheng injection and chemotherapy in elderly patients with non-small cell lungcancer （ NSCLC） , and to observe its effect on immune function and serum tumor markers of carcino embryonie antigen （ CEA） , carbohydrate antigen 19-9 （CA19-9） , cytokeratin 19 fragment （CYFRA21-1） and neuronspecific enolase （ NSE）. Methods 80 patients with NSCLC who were confirmed as non-small cell lung cancer were enrolled in the study. Among them, the control group received paclitaxel ＋ carboplatin chemotherapy, 40 patients; the treatment group received Shenqi Fuzheng injection on the basis of the control group , 40 cases. The clinical curative effect was evaluated after four cyclesof treatment and the adverse reactions were recorded. The scores of traditional Chinese medicine （ TCM） syndrome before and after four cycles oftreatment were evaluated, and the quality of life of the patients before and after treatment were evaluated by Karnofsky performance score （ KPS）. The immune function and tumor markers were measured before and after treatment. Results The total effective rate of the treatment group was 65. 0% , which was significantly higher than that of the control group （42. 5% χ2 = 4. 07, P = 0. 04 ） . In the treatment group, the adverse reaction rate was 37. 5% , significantly lower than 62. 5% in the control group （χ2 =5. 00, P =0. 02）. The score of TCM syndrome in the two groups was significantly lower than that in the control group before treatment, and the KPS score was significantly higher than that in the control group before treatment, the score of TCM syndrome in the treatment group was significantly lower than that in the control group（P 〈0. 05）. After treatment, the immune function of patients in the treatment group compared with before treatment had no significant difference, while the control group after treatment of the immune function was significantly lower than b
出处
《中国生化药物杂志》
CAS
2017年第4期69-71,74,共4页
Chinese Journal of Biochemical Pharmaceutics
关键词
非小细胞肺癌
老年
参芪扶正注射液
化疗
肿瘤标志物
免疫功能
non-small cell lung cancer senile Shenqi Fuzheng injection chemotherapy tumor markers immune function
